Project Grant R01CA303520
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $645K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.71 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 1, 2025, through July 31, 2032. The award supports research into new approaches for targeting cell cycle proteins in cancer treatment, specifically focusing on cyclin-dependent kinase (CDK) inhibitor development and therapeutic applications. The research addresses critical...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute a Project Grant of $683,075 under the Cancer Cause and Prevention Research program (CFDA 93.393), with an award date of March 24, 2026, and a completion date of February 28, 2031. This research initiative, titled "TIRR/53BP1 Complex Regulates Mitotic Fidelity and Immune-Mediated Radiation Response," investigates the mitotic functions of 53BP1, a protein critical to genome stability...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $463,279 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2026 through June 30, 2031. This award supports research investigating USP1 (ubiquitin-specific peptidase 1) inhibition as a therapeutic strategy to overcome PARP (poly ADP-ribose polymerase) inhibitor resistance in high-grade serous ovarian cancer (HGSOC) with homologous recombination...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $134,919 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective June 11, 2026, with completion targeted for May 31, 2028. This award supports biomedical research training and career development focused on cancer research aligned with the National Cancer Program's strategic priorities. The institute will leverage this funding to provide research...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $341,280 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective July 1, 2025 through June 30, 2027. This award supports a K99/R00 Pathway to Independence research project investigating the role of histone cleavage in triple-negative breast cancer (TNBC), with emphasis on understanding the KDM4C histone demethylase protein and its tumorigenic mechanisms....
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School a $237,023 Project Grant under the Cancer Biology Research program (CFDA 93.396) on March 13, 2026, with completion scheduled for February 28, 2029. The grant funds development of high-throughput technological tools to track the fate of prematurely terminated transcripts in cancer cells, specifically focusing on alternative polyadenylation (APA) events. The research addresses a critical gap in...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a Project Grant of $275,990 under the Cancer Research Manpower program (CFDA 93.398) effective September 2, 2025, with completion targeted for August 31, 2026. This award supports the development of engineered living materials (ELMs) as programmable therapeutic implants for pancreatic ductal adenocarcinoma (PDAC), a devastating cancer with a five-year survival rate below 5%. The primary...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill a Project Grant of $627,676 under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025 through August 31, 2028. This three-year research initiative focuses on developing and validating genetically-encoded biosensors to characterize intercellular heterogeneity in cell cycle quiescence—specifically the spectrum of quiescent (dormant) states in cancer...